Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 205

1.

Novel CD19-targeted TriKE restores NK cell function and proliferative capacity in CLL.

Felices M, Kodal B, Hinderlie P, Kaminski MF, Cooley S, Weisdorf DJ, Vallera DA, Miller JS, Bachanova V.

Blood Adv. 2019 Mar 26;3(6):897-907. doi: 10.1182/bloodadvances.2018029371.

2.

3D Bioprinted In Vitro Metastatic Models via Reconstruction of Tumor Microenvironments.

Meng F, Meyer CM, Joung D, Vallera DA, McAlpine MC, Panoskaltsis-Mortari A.

Adv Mater. 2019 Mar;31(10):e1806899. doi: 10.1002/adma.201806899. Epub 2019 Jan 21.

PMID:
30663123
3.

Immunotoxins Targeting B cell Malignancy-Progress and Problems With Immunogenicity.

Vallera DA, Kreitman RJ.

Biomedicines. 2018 Dec 21;7(1). pii: E1. doi: 10.3390/biomedicines7010001. Review.

4.

Targeting EGFR and uPAR on human rhabdomyosarcoma, osteosarcoma, and ovarian adenocarcinoma with a bispecific ligand-directed toxin.

Oh F, Todhunter D, Taras E, Vallera DA, Borgatti A.

Clin Pharmacol. 2018 Sep 26;10:113-121. doi: 10.2147/CPAA.S160262. eCollection 2018.

5.

Trispecific killer engager CD16xIL15xCD33 potently induces NK cell activation and cytotoxicity against neoplastic mast cells.

Yun HD, Felices M, Vallera DA, Hinderlie P, Cooley S, Arock M, Gotlib J, Ustun C, Miller JS.

Blood Adv. 2018 Jul 10;2(13):1580-1584. doi: 10.1182/bloodadvances.2018018176. No abstract available.

6.

161533 TriKE stimulates NK-cell function to overcome myeloid-derived suppressor cells in MDS.

Sarhan D, Brandt L, Felices M, Guldevall K, Lenvik T, Hinderlie P, Curtsinger J, Warlick E, Spellman SR, Blazar BR, Weisdorf DJ, Cooley S, Vallera DA, Önfelt B, Miller JS.

Blood Adv. 2018 Jun 26;2(12):1459-1469. doi: 10.1182/bloodadvances.2017012369.

7.

Targeting pediatric sarcoma with a bispecific ligand immunotoxin targeting urokinase and epidermal growth factor receptors.

Pilbeam K, Wang H, Taras E, Bergerson RJ, Ettestad B, DeFor T, Borgatti A, Vallera DA, Verneris MR.

Oncotarget. 2017 Sep 23;9(15):11938-11947. doi: 10.18632/oncotarget.21187. eCollection 2018 Feb 23.

8.

Early Reconstitution of NK and γδ T Cells and Its Implication for the Design of Post-Transplant Immunotherapy.

de Witte MA, Sarhan D, Davis Z, Felices M, Vallera DA, Hinderlie P, Curtsinger J, Cooley S, Wagner J, Kuball J, Miller JS.

Biol Blood Marrow Transplant. 2018 Jun;24(6):1152-1162. doi: 10.1016/j.bbmt.2018.02.023. Epub 2018 Mar 2.

9.

Development of a Deimmunized Bispecific Immunotoxin dDT2219 against B-Cell Malignancies.

Schmohl JU, Todhunter D, Taras E, Bachanova V, Vallera DA.

Toxins (Basel). 2018 Jan 6;10(1). pii: E32. doi: 10.3390/toxins10010032.

10.

Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy.

Davis ZB, Vallera DA, Miller JS, Felices M.

Semin Immunol. 2017 Jun;31:64-75. doi: 10.1016/j.smim.2017.07.011. Epub 2017 Sep 5. Review.

11.

Engineering of Anti-CD133 Trispecific Molecule Capable of Inducing NK Expansion and Driving Antibody-Dependent Cell-Mediated Cytotoxicity.

Schmohl JU, Felices M, Oh F, Lenvik AJ, Lebeau AM, Panyam J, Miller JS, Vallera DA.

Cancer Res Treat. 2017 Oct;49(4):1140-1152. doi: 10.4143/crt.2016.491. Epub 2017 Feb 20.

12.

Evaluation of 18-F-fluoro-2-deoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) as a staging and monitoring tool for dogs with stage-2 splenic hemangiosarcoma - A pilot study.

Borgatti A, Winter AL, Stuebner K, Scott R, Ober CP, Anderson KL, Feeney DA, Vallera DA, Koopmeiners JS, Modiano JF, Froelich J.

PLoS One. 2017 Feb 21;12(2):e0172651. doi: 10.1371/journal.pone.0172651. eCollection 2017.

13.

Safe and Effective Sarcoma Therapy through Bispecific Targeting of EGFR and uPAR.

Borgatti A, Koopmeiners JS, Sarver AL, Winter AL, Stuebner K, Todhunter D, Rizzardi AE, Henriksen JC, Schmechel S, Forster CL, Kim JH, Froelich J, Walz J, Henson MS, Breen M, Lindblad-Toh K, Oh F, Pilbeam K, Modiano JF, Vallera DA.

Mol Cancer Ther. 2017 May;16(5):956-965. doi: 10.1158/1535-7163.MCT-16-0637. Epub 2017 Feb 13.

14.

Allogeneic NK cells eradicate myeloblasts but not neoplastic mast cells in systemic mastocytosis associated with acute myeloid leukemia.

Ustun C, Williams S, Skendzel S, Kodal B, Arock M, Gotlib J, Vallera DA, Cooley S, Felices M, Weisdorf D, Miller J.

Am J Hematol. 2017 May;92(5):E66-E68. doi: 10.1002/ajh.24673. Epub 2017 Feb 24. No abstract available.

15.

Tetraspecific scFv construct provides NK cell mediated ADCC and self-sustaining stimuli via insertion of IL-15 as a cross-linker.

Schmohl JU, Felices M, Todhunter D, Taras E, Miller JS, Vallera DA.

Oncotarget. 2016 Nov 8;7(45):73830-73844. doi: 10.18632/oncotarget.12073.

16.

CD133, Selectively Targeting the Root of Cancer.

Schmohl JU, Vallera DA.

Toxins (Basel). 2016 May 28;8(6). pii: E165. doi: 10.3390/toxins8060165. Review.

17.

Generation of BiKEs and TriKEs to Improve NK Cell-Mediated Targeting of Tumor Cells.

Felices M, Lenvik TR, Davis ZB, Miller JS, Vallera DA.

Methods Mol Biol. 2016;1441:333-46. doi: 10.1007/978-1-4939-3684-7_28.

18.

Enhanced ADCC and NK Cell Activation of an Anticarcinoma Bispecific Antibody by Genetic Insertion of a Modified IL-15 Cross-linker.

Schmohl JU, Felices M, Taras E, Miller JS, Vallera DA.

Mol Ther. 2016 Aug;24(7):1312-22. doi: 10.1038/mt.2016.88. Epub 2016 May 9.

19.

IL15 Trispecific Killer Engagers (TriKE) Make Natural Killer Cells Specific to CD33+ Targets While Also Inducing Persistence, In Vivo Expansion, and Enhanced Function.

Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS.

Clin Cancer Res. 2016 Jul 15;22(14):3440-50. doi: 10.1158/1078-0432.CCR-15-2710. Epub 2016 Feb 4.

20.

Heterodimeric Bispecific Single Chain Variable Fragments (scFv) Killer Engagers (BiKEs) Enhance NK-cell Activity Against CD133+ Colorectal Cancer Cells.

Schmohl JU, Gleason MK, Dougherty PR, Miller JS, Vallera DA.

Target Oncol. 2016 Jun;11(3):353-61. doi: 10.1007/s11523-015-0391-8.

21.

Mutagenic Deimmunization of Diphtheria Toxin for Use in Biologic Drug Development.

Schmohl JU, Todhunter D, Oh S, Vallera DA.

Toxins (Basel). 2015 Oct 10;7(10):4067-82. doi: 10.3390/toxins7104067.

22.

A novel brain metastasis xenograft model for convection‑enhanced delivery of targeted toxins via a micro‑osmotic pump system enabled for real‑time bioluminescence imaging.

Huang J, Li YM, Cheng Q, Vallera DA, Hall WA.

Mol Med Rep. 2015 Oct;12(4):5163-8. doi: 10.3892/mmr.2015.4111. Epub 2015 Jul 22.

PMID:
26238362
23.

Prosthetic Antigen Receptors.

Shen J, Vallera DA, Wagner CR.

J Am Chem Soc. 2015 Aug 19;137(32):10108-11. doi: 10.1021/jacs.5b06166. Epub 2015 Aug 6.

PMID:
26230248
24.

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.

Bachanova V, Frankel AE, Cao Q, Lewis D, Grzywacz B, Verneris MR, Ustun C, Lazaryan A, McClune B, Warlick ED, Kantarjian H, Weisdorf DJ, Miller JS, Vallera DA.

Clin Cancer Res. 2015 Mar 15;21(6):1267-72. doi: 10.1158/1078-0432.CCR-14-2877.

25.

CD16xCD33 bispecific killer cell engager (BiKE) activates NK cells against primary MDS and MDSC CD33+ targets.

Gleason MK, Ross JA, Warlick ED, Lund TC, Verneris MR, Wiernik A, Spellman S, Haagenson MD, Lenvik AJ, Litzow MR, Epling-Burnette PK, Blazar BR, Weiner LM, Weisdorf DJ, Vallera DA, Miller JS.

Blood. 2014 May 8;123(19):3016-26. doi: 10.1182/blood-2013-10-533398. Epub 2014 Mar 20.

26.

A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.

Waldron NN, Barsky SH, Dougherty PR, Vallera DA.

Target Oncol. 2014 Sep;9(3):239-49. doi: 10.1007/s11523-013-0290-9. Epub 2013 Jul 31.

27.

Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.

Skubitz AP, Taras EP, Boylan KL, Waldron NN, Oh S, Panoskaltsis-Mortari A, Vallera DA.

Gynecol Oncol. 2013 Sep;130(3):579-87. doi: 10.1016/j.ygyno.2013.05.027. Epub 2013 May 27.

28.

Diphtheria toxin-based targeted toxin therapy for brain tumors.

Li YM, Vallera DA, Hall WA.

J Neurooncol. 2013 Sep;114(2):155-64. doi: 10.1007/s11060-013-1157-8. Epub 2013 May 22. Review.

PMID:
23695514
29.

Targeting natural killer cells to acute myeloid leukemia in vitro with a CD16 x 33 bispecific killer cell engager and ADAM17 inhibition.

Wiernik A, Foley B, Zhang B, Verneris MR, Warlick E, Gleason MK, Ross JA, Luo X, Weisdorf DJ, Walcheck B, Vallera DA, Miller JS.

Clin Cancer Res. 2013 Jul 15;19(14):3844-55. doi: 10.1158/1078-0432.CCR-13-0505. Epub 2013 May 20.

30.

Heterodimeric bispecific single-chain variable-fragment antibodies against EpCAM and CD16 induce effective antibody-dependent cellular cytotoxicity against human carcinoma cells.

Vallera DA, Zhang B, Gleason MK, Oh S, Weiner LM, Kaufman DS, McCullar V, Miller JS, Verneris MR.

Cancer Biother Radiopharm. 2013 May;28(4):274-82. doi: 10.1089/cbr.2012.1329. Epub 2013 Apr 23.

31.

Hemangiosarcoma and its cancer stem cell subpopulation are effectively killed by a toxin targeted through epidermal growth factor and urokinase receptors.

Schappa JT, Frantz AM, Gorden BH, Dickerson EB, Vallera DA, Modiano JF.

Int J Cancer. 2013 Oct 15;133(8):1936-44. doi: 10.1002/ijc.28187. Epub 2013 Apr 25. Erratum in: Int J Cancer. 2018 Nov 15;143(10):E11.

32.

Immunotoxin targeting CD133(+) breast carcinoma cells.

Ohlfest JR, Zellmer DM, Panyam J, Swaminathan SK, Oh S, Waldron NN, Toma S, Vallera DA.

Drug Deliv Transl Res. 2013 Apr;3(2):195-204. doi: 10.1007/s13346-012-0066-2.

PMID:
25787984
33.

Identification and characterization of a novel scFv recognizing human and mouse CD133.

Swaminathan SK, Niu L, Waldron N, Kalscheuer S, Zellmer DM, Olin MR, Ohlfest JR, Vallera DA, Panyam J.

Drug Deliv Transl Res. 2013 Apr;3(2):143-51. doi: 10.1007/s13346-012-0099-6.

34.

Bispecific and trispecific killer cell engagers directly activate human NK cells through CD16 signaling and induce cytotoxicity and cytokine production.

Gleason MK, Verneris MR, Todhunter DA, Zhang B, McCullar V, Zhou SX, Panoskaltsis-Mortari A, Weiner LM, Vallera DA, Miller JS.

Mol Cancer Ther. 2012 Dec;11(12):2674-84. doi: 10.1158/1535-7163.MCT-12-0692. Epub 2012 Oct 17.

35.

Bispecific targeting of EGFR and uPAR in a mouse model of head and neck squamous cell carcinoma.

Waldron NN, Oh S, Vallera DA.

Oral Oncol. 2012 Dec;48(12):1202-7. doi: 10.1016/j.oraloncology.2012.06.002. Epub 2012 Jul 20.

36.

Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer.

Huang J, Li YM, Massague J, Sicheneder A, Vallera DA, Hall WA.

J Neurooncol. 2012 Sep;109(2):229-38. doi: 10.1007/s11060-012-0904-6. Epub 2012 Jun 14.

PMID:
22696210
37.

A deimmunized bispecific ligand-directed toxin that shows an impressive anti-pancreatic cancer effect in a systemic nude mouse orthotopic model.

Oh S, Todhunter DA, Panoskaltsis-Mortari A, Buchsbaum DJ, Toma S, Vallera DA.

Pancreas. 2012 Jul;41(5):789-96. doi: 10.1097/MPA.0b013e31823b5f2e.

38.

Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.

Waldron NN, Kaufman DS, Oh S, Inde Z, Hexum MK, Ohlfest JR, Vallera DA.

Mol Cancer Ther. 2011 Oct;10(10):1829-38. doi: 10.1158/1535-7163.MCT-11-0206. Epub 2011 Aug 23.

39.

Evaluation of a bispecific biological drug designed to simultaneously target glioblastoma and its neovasculature in the brain.

Oh S, Tsai AK, Ohlfest JR, Panoskaltsis-Mortari A, Vallera DA.

J Neurosurg. 2011 Jun;114(6):1662-71. doi: 10.3171/2010.11.JNS101214. Epub 2011 Feb 4.

PMID:
21294620
40.

Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.

Li Q, So CR, Fegan A, Cody V, Sarikaya M, Vallera DA, Wagner CR.

J Am Chem Soc. 2010 Dec 8;132(48):17247-57. doi: 10.1021/ja107153a. Epub 2010 Nov 15.

41.

A novel bispecific ligand-directed toxin designed to simultaneously target EGFR on human glioblastoma cells and uPAR on tumor neovasculature.

Tsai AK, Oh S, Chen H, Shu Y, Ohlfest JR, Vallera DA.

J Neurooncol. 2011 Jun;103(2):255-66. doi: 10.1007/s11060-010-0392-5. Epub 2010 Sep 10.

42.

Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia.

Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR.

Blood. 2010 Oct 7;116(14):2484-93. doi: 10.1182/blood-2010-03-275446. Epub 2010 Jun 22.

43.

Bioengineering a unique deimmunized bispecific targeted toxin that simultaneously recognizes human CD22 and CD19 receptors in a mouse model of B-cell metastases.

Vallera DA, Oh S, Chen H, Shu Y, Frankel AE.

Mol Cancer Ther. 2010 Jun;9(6):1872-83. doi: 10.1158/1535-7163.MCT-10-0203. Epub 2010 Jun 8.

44.

A new drug delivery method of bispecific ligand-directed toxins, which reduces toxicity and promotes efficacy in a model of orthotopic pancreatic cancer.

Oh S, Stish BJ, Vickers SM, Buchsbaum DJ, Saluja AK, Vallera DA.

Pancreas. 2010 Aug;39(6):913-22. doi: 10.1097/MPA.0b013e3181cbd908.

45.

A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.

Oh S, Stish BJ, Sachdev D, Chen H, Dudek AZ, Vallera DA.

Clin Cancer Res. 2009 Oct 1;15(19):6137-47. doi: 10.1158/1078-0432.CCR-09-0696. Epub 2009 Sep 29.

46.

Design and modification of EGF4KDEL 7Mut, a novel bispecific ligand-directed toxin, with decreased immunogenicity and potent anti-mesothelioma activity.

Stish BJ, Oh S, Chen H, Dudek AZ, Kratzke RA, Vallera DA.

Br J Cancer. 2009 Oct 6;101(7):1114-23. doi: 10.1038/sj.bjc.6605297.

47.

Depletion of endogenous tumor-associated regulatory T cells improves the efficacy of adoptive cytotoxic T-cell immunotherapy in murine acute myeloid leukemia.

Zhou Q, Bucher C, Munger ME, Highfill SL, Tolar J, Munn DH, Levine BL, Riddle M, June CH, Vallera DA, Weigel BJ, Blazar BR.

Blood. 2009 Oct 29;114(18):3793-802. doi: 10.1182/blood-2009-03-208181. Epub 2009 Sep 1.

48.

Intracranial elimination of human glioblastoma brain tumors in nude rats using the bispecific ligand-directed toxin, DTEGF13 and convection enhanced delivery.

Oh S, Ohlfest JR, Todhunter DA, Vallera VD, Hall WA, Chen H, Vallera DA.

J Neurooncol. 2009 Dec;95(3):331-342. doi: 10.1007/s11060-009-9932-2. Epub 2009 Jun 11.

PMID:
19517064
49.

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.

Vallera DA, Chen H, Sicheneder AR, Panoskaltsis-Mortari A, Taras EP.

Leuk Res. 2009 Sep;33(9):1233-42. doi: 10.1016/j.leukres.2009.02.006. Epub 2009 Mar 26.

50.

Self-assembly of antibodies by chemical induction.

Li Q, Hapka D, Chen H, Vallera DA, Wagner CR.

Angew Chem Int Ed Engl. 2008;47(52):10179-82. doi: 10.1002/anie.200803507. No abstract available.

Supplemental Content

Loading ...
Support Center